276 related articles for article (PubMed ID: 10595660)
1. The importance of differentiating ReoPro (c7E3 abciximab) induced thrombocytopenia from heparin-induced thrombocytopenia.
Davidson SJ; Turner N; Clague JR; Oldershaw PJ; Burman JF
Thromb Haemost; 1999 Nov; 82(5):1560-1. PubMed ID: 10595660
[No Abstract] [Full Text] [Related]
2. Images in cardiovascular medicine. Abciximab-associated pseudothrombocytopenia.
Holmes MB; Kabbani S; Watkins MW; Battle RW; Schneider DJ
Circulation; 2000 Feb; 101(8):938-9. PubMed ID: 10694535
[No Abstract] [Full Text] [Related]
3. A case of pseudothrombocytopenia after infusion of abciximab in vivo and anticoagulant-independent platelet clumping after rechallenge with abciximab in vitro.
Kozak M; Dovc T; Rozman P; Blinc A
Wien Klin Wochenschr; 2000 Feb; 112(3):138-41. PubMed ID: 10729966
[TBL] [Abstract][Full Text] [Related]
4. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
5. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.
Berkowitz SD; Harrington RA; Rund MM; Tcheng JE
Circulation; 1997 Feb; 95(4):809-13. PubMed ID: 9054735
[TBL] [Abstract][Full Text] [Related]
6. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
Nguyen N; Salib H; Mascarenhas DA
J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
[TBL] [Abstract][Full Text] [Related]
7. Acute profound thrombocytopenia following abciximab therapy.
Bishara AI; Hagmeyer KO
Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
[TBL] [Abstract][Full Text] [Related]
8. Acute stent thrombosis associated with heparin-induced thrombocytopenia and abciximab-induced profound thrombocytopenia.
Dasari TW; Pappy R; Hennebry TA
J Invasive Cardiol; 2011 Feb; 23(2):E5-8. PubMed ID: 21297217
[TBL] [Abstract][Full Text] [Related]
9. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature.
Makoni SN
Heart; 2001 Dec; 86(6):E18. PubMed ID: 11711483
[TBL] [Abstract][Full Text] [Related]
10. Profound delayed thrombocytopenia presenting 16 days after Abciximab (Reopro®) administration.
Webb GJ; Swinburn JM; Grech H
Platelets; 2011; 22(4):302-4. PubMed ID: 21526887
[TBL] [Abstract][Full Text] [Related]
11. Acute profound thrombocytopenia without bleeding complications after abciximab administration.
Elmi F; Oza R; Mascarenhas DA
J Invasive Cardiol; 1999 May; 11(5):313-5. PubMed ID: 10745539
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
[TBL] [Abstract][Full Text] [Related]
13. Reversal of recurrent thrombocytopenia due to abciximab.
Sharma V; Mascarenhas D
J Invasive Cardiol; 2004 Sep; 16(9):537-8. PubMed ID: 15353816
[No Abstract] [Full Text] [Related]
14. Abciximab-induced thrombocytopenia: management of bleeding in the setting of recent coronary stents.
Nowakowski K; Rogers J; Nelson G; Gunalingam B
J Interv Cardiol; 2008 Feb; 21(1):100-5. PubMed ID: 18194210
[TBL] [Abstract][Full Text] [Related]
15. Fatal delayed thrombocytopenia following abciximab therapy.
McCorry RB; Johnston P
J Invasive Cardiol; 2006 Jun; 18(6):E173-4. PubMed ID: 16775895
[No Abstract] [Full Text] [Related]
16. [Profound thrombocytopenia after abciximab administration in acute myocardial infarction and stent thrombosis following thrombocytopenia remission--a case report].
Elikowski W; Rzeźniczak J; Słomczyński M; Psuja P
Kardiol Pol; 2005 Jan; 62(1):44-7; discussion 48. PubMed ID: 15815778
[TBL] [Abstract][Full Text] [Related]
17. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
18. Acute severe thrombocytopenia after treatment with ReoPro (abciximab).
Butler R; Hubner PJ
Heart; 2000 Apr; 83(4):E5. PubMed ID: 10722557
[TBL] [Abstract][Full Text] [Related]
19. Thrombocytopenia associated with c7E3 Fab (abciximab).
Schell DA; Ganti AK; Levitt R; Potti A
Ann Hematol; 2002 Feb; 81(2):76-9. PubMed ID: 11907786
[TBL] [Abstract][Full Text] [Related]
20. Abciximab readministration: results of the ReoPro Readministration Registry.
Tcheng JE; Kereiakes DJ; Lincoff AM; George BS; Kleiman NS; Sane DC; Cines DB; Jordan RE; Mascelli MA; Langrall MA; Damaraju L; Schantz A; Effron MB; Braden GA
Circulation; 2001 Aug; 104(8):870-5. PubMed ID: 11514371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
